UNSPSC 51401512: Menitrazepam

This classification denotes a benzodiazepine with the molecular formula C16H17N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1243654WZK, chemically known as 2h-1,4-benzodiazepin-2-one, 5-(1-cyclohexen-1-yl)-1,3-dihydro-1-methyl-7-nitro- but generally known as menitrazepam, which bears US NIH Compound Identifier 189875. European Medicines Agency schedules Menitrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08740MIG.

UNSPSC 51401512 Menitrazepam, a Commodity code, nominally describes a specific pharmaceutical substance, but recent state and local solicitations tagged under this code reflect broader pharmaceutical procurement covering generic multi-source drugs, over-the-counter products, naloxone, and drug deactivation systems rather than menitrazepam specifically. State and local buyers under this code include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The work involves establishing framework agreements with pharmaceutical manufacturers and wholesalers to supply medications and related health products to public health programs, community health initiatives, and state employee benefit plans on fixed-fee or negotiated pricing models with quarterly or ongoing deliveries.

Geographic activity spans Florida, Texas, and Minnesota, with procurement structured through both individual county health departments and regional cooperative purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, seeking manufacturers to supply through three authorized wholesalers with pricing effective July 1, 2026. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program, indicating early-stage market research that may lead to a formal RFP. Vendors must maintain FDA compliance, cGMP certification where applicable, Drug Supply Chain Security Act adherence, and substantial insurance coverage including commercial general liability of $2 million to $5 million per occurrence.